Neuropharmaceutical company focusing on novel development of novel rapid-acting treatments for mental conditions like depression Small Pharma Inc. (TSXV: DMT) announced having appointed Ms. Lyne Fortin as a non-executive independent chair of the company’s board of directors.
Going forward, Fortin will hold the office until the next general annual meeting by shareholders or until when her successor will be appointed or elected.
Since April this year, Fortin has been serving as a director of the company, she will also continue to serve her other roles at the company which includes chair of the Corporate Governance and Nominating Committee and the Compensation Committee.
“I am honored to be Chair of the Board of Small Pharma as the growing burden of mental health is in need of ground-breaking solutions. Small Pharma represents the perfect match of a clearly differentiated program in psychedelic research, with the drive of a strong and passionate team to deliver tangible results,” said Fortin who is also a member of the Audit Committee.